Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.

Tiffany C Ho,Robi N Maamari,Andrea L Kossler,Connie M Sears,Suzanne K Freitag,Edith R Reshef,Roman Shinder,Daniel B Rootman,Stefania B Diniz,Alon Kahana, Dianne Schlachter, Thai H Do,Peter Kally,Sara Turner,Ali Mokhtarzadeh,Andrew R Harrison, Christopher J Hwang,Hee Joon Kim,Sarah A Avila,Dilip A Thomas, Maja Magazin,Sara T Wester,Wendy W Lee,Kevin D Clauss,John B Holds,Matthew Sniegowski,Christopher J Compton, Christian Briggs,Amina I Malik,Mark J Lucarelli,Cat N Burkat, Luv G Patel,Steven M Couch

Ophthalmic plastic and reconstructive surgery（2023）

引用 3|浏览12

暂无评分

摘要

Patients partially treated with teprotumumab achieve significant reduction in proptosis, CAS, and extraocular muscle restriction and maintain these improvements through the period of interruption.

查看译文

关键词

thyroid eye disease,teprotumumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要